Although the spread of typhoid fever can be controlled by sanitation, vaccination is the method -used for controlling this disease in many parts of the world. Field trials (1954) (1955) (1956) (1957) (1958) (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) in Yugoslavia, Guyana, Poland, and the U.S.S.R. (5) have shown that inactivated cellular vaccines offered significant protection, and the acetone-inactivated vaccine K was more protective than the heat-phenol-inactivated vaccine L. Unfortunately, adverse reactions due to endotoxin or other toxic substances are frequent in vaccines.
Many attempts have been made to identify and isolate protective antigens from the typhoid bacillus. However, no single component has been identified as protective in human immunity. Despite its importance in animals (7, 12, 22) , the role of Vi antigen in human immunity remains to be ascertained. As a result of our study of laboratory assay methods for control of typhoid vaccines, we isolated a Vi antigen from Salmonella typhosa by precipitation with hexadecyltrimethylammonium bromide (Cetavlon) (1, 21) , and studied its immunological properties in animals and tissue cultures. It appeared to be more potent than preparations used in the past in human studies (9) . The isolation procedures and some immunological properties of this Vi preparation are described here. Study of this antigen in human volunteers is in progress. ' Present address: University of Hawaii Postgraduate Medical Education Program, Okinawa Central Hospital. Gushikawa City, Okinawa, Japan. 348
MATERIALS AND METHODS Culture. Bacterial cultures were grown on veal inf'usion agar (Difco Laboratories, Detroit, Mich.) at 37 C overnight. S. typhosa strain Ty 2 was treated with acetone as previously described (22) . S. typhosa 0901 (a Vi-negative strain) was harvested, washed three times, and pasteurized in saline before being used for absorption experiments. S. typhosa M 4702 and E-2322-72 were multiple-antibiotic-resistant strains isolated from recent epidemics and obtained from the Center for Disease Control, Atlanta, Ga.
Vaccines. The U.S. Standard Typhoid Vaccine lot 6A, acetone-inactivated and dried, and typhoid vaccine L, heat-phenol-killed and dried, were prepared from S. typhosa strain Ty 2 and standardized by bacterial counts (6, 22) .
Isolation of Vi antigen preparations. The procedure for isolation of Vi antigen (Vi-Ty 2) from S. typhosa Ty 2 is given in Fig. 1 The active mouse protection test was performed as described previously (22) . Toxicity was assayed by the actinomycin D enhancement test in mice (23) .
For lymphocyte transformation assay, mice weighing 16 to 18 g each were immunized intraperitoneally with 10 ,ug of a Vi preparation or with 107 cells of a conventional typhoid vaccine in 1 ml of saline. Control mice were given 1 ml of saline. (Table 2) .
Protective activities in mice. (2) . Only the ability to stimulate H antibody appeared to correlate with efficacy in the field. However, H antibody was not protective in mice (16) , and no immunity was observed in chimpanzees having high H antibody titers induced by vaccination with a rough strain of S. typhosa (17) . This correlation, therefore, appears to be spurious and may indicate the involvement of other antigens of similar lability (11) .
The ability of the 0 antigen to protect man was tested in a field trial in Poland by using a Westphal-type lipopolysaccharide stimulating VOL 9, 1974 only 0 antibody. This preparation was without protective effectiveness (11) .
Despite its importance as demonstrated in animals (7), the role of the Vi antigen in human immunity has not been clearly delineated. Besides the lack of correlation between circulating Vi antibody and immunity (2), no significant protection was obtained in human volunteers immunized with purified Vi antigen from Citrobacter (9) . However, there is evidence which argues for a role of Vi antigen in human protection: (i) Vi antigen is characteristic of virulent strains of S. typhosa as first demonstrated in mice by Felix and Pitt (7) and recently by Hornick and associates (9) (22) . The acetone-inactivated vaccine used in the field trials was superior to the heat-phenol-inactivated vaccine in human and animal protection (5, 15) . It was shown that the major difference between these two vaccines was in their Vi antigen. Acetone fixed the Vi tightly to the bacteria, whereas the Vi in the heat-phenol-inactivated vaccine dissolved away (Wong et (9) . Both Vi-W, and Vi-W2 were not from S. typhosa but were isolated from Citrobacter 5396/38 by the method of Webster et al. (19) , which involved hot-acid hydrolysis for removal of endotoxin. The isolation method described here was quite mild in comparison and appeared to preserve protective activity better. It was also found that Vi-W, and Vi-W2 behaved like a degraded antigen in immunodiffusion in agar gel in contrast to the Vi-Ty 2. Comparing Vi-Ty 2 with the whole-cell, acetone-inactivated vaccine 6A, it was found that Vi-Ty 2 was nine times more potent in protecting mice relative to the esti- It was demonstrated here that Vi antibody possessed bactericidal activity against different strains of S. typhosa. Although there is a correlation of bactericidal activity to protection against some gram-negative organisms, in particular the meningococci (8), the role of bactericidal antibody in typhoid fever is not clear. However, it is conceivable that it may have some protective value, especially when the organism invades the blood stream.
Vi-Ty 2 was about three times more active than Vi-W, in stimulating transformation of mouse lymphoid cells. It is unlikely that this was due to the slight contamination of endotoxin in the Vi-Ty 2 preparation. The significance of this difference as related to cellular immunity or humoral antibody responses remains to be clarified. These experiments indicate that the Vi-Ty 2 preparation from S. typhosa was substantially reduced in endotoxin content from conventional cellular vaccine, and, in the mouse protection system, was enhanced in its protective effect. Study of this antigen in human volunteers is in progress with emphasis on the cellular immune system, as well as antibody response, particularly intestinal antibody. It is hoped that with a potent antigen preparation from the causative pathogen, the role of the Vi antigen in human typhoid immunity will be better defined. 
